Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Liver Transplant
Interventions
DRUG

treprostinil sodium

"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"

DRUG

Placebo

Trial Locations (1)

15213

University of Pittsburgh Medical Center, Starzl Transplantation Institute, Pittsburgh

Sponsors
All Listed Sponsors
collaborator

University of Pittsburgh Medical Center

OTHER

lead

United Therapeutics

INDUSTRY

NCT01884038 - Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients | Biotech Hunter | Biotech Hunter